Skip to content

Study · Randomized controlled trial · n = 3,692 · 2018

3 results

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP

Circulation1 Dec 2018Cited by 95 (Europe PMC)

PMID30566004 (opens in a new tab)DOI10.1161/circulationaha.118.034516 (opens in a new tab)PepBankPUB-30566004
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and a history of MI or stroke, liraglutide reduced major adverse cardiovascular events versus placebo (hazard ratio 0.85).

    In plain wordsIn adults with type 2 diabetes and a past heart attack or stroke, liraglutide led to fewer major heart and stroke events than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMajor adverse cardiovascular events in patients with prior MI or stroke
    Study

    n = 3,692

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mg or maximum tolerated dose · median follow-up 3.8 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    0.85
    history of MI/stroke

    Source sentences

    Summary
    Liraglutide reduced major adverse cardiovascular events in patients with a history of MI/stroke (322 of 1865 [17.3%] versus 372 of 1827 patients [20.4%]; hazard ratio, 0.85; 95% CI, 0.73-0.99)
    1 context sentence
    Summary · context
    LEADER was a randomized trial of liraglutide (1.8 mg or maximum tolerated dose) versus placebo in 9340 patients with type 2 diabetes mellitus and high cardiovascular risk, with a median follow-up of 3.8 years.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and established atherosclerotic cardiovascular disease without prior MI or stroke, liraglutide reduced major adverse cardiovascular events versus placebo (hazard ratio 0.76).

    In plain wordsIn adults with type 2 diabetes and established artery disease, liraglutide led to fewer major heart and stroke events than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMajor adverse cardiovascular events in patients with established ASCVD without MI or stroke
    Study

    n = 3,083

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mg or maximum tolerated dose · median follow-up 3.8 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    0.76
    established ASCVD without MI/stroke

    Source sentences

    Summary
    and in those with established atherosclerotic cardiovascular disease without MI/stroke (158 of 1538 [10.3%] versus 199 of 1545 patients [12.9%]; hazard ratio, 0.76; 95% CI, 0.62-0.94) compared with placebo.
    1 context sentence
    Summary · context
    LEADER was a randomized trial of liraglutide (1.8 mg or maximum tolerated dose) versus placebo in 9340 patients with type 2 diabetes mellitus and high cardiovascular risk, with a median follow-up of 3.8 years.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and cardiovascular risk factors alone, liraglutide did not significantly change major adverse cardiovascular events versus placebo (hazard ratio 1.08).

    In plain wordsIn adults with type 2 diabetes and only risk factors, liraglutide did not clearly change major heart and stroke events compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMajor adverse cardiovascular events in patients with risk factors alone
    Study

    n = 2,565

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    1.8 mg or maximum tolerated dose · median follow-up 3.8 yearsAs given in this study (human).

    Measurements

    Hazard ratio
    1.08
    risk factors alone

    Source sentences

    Summary
    In patients with risk factors alone, the hazard ratio for liraglutide versus placebo was 1.08 (95% CI, 0.84-1.38, Pinteraction=0.11).
    1 context sentence
    Summary · context
    LEADER was a randomized trial of liraglutide (1.8 mg or maximum tolerated dose) versus placebo in 9340 patients with type 2 diabetes mellitus and high cardiovascular risk, with a median follow-up of 3.8 years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.